CTOs on the Move

Vitro Biopharma

www.vitrobiopharma.com

 
Vitro Biopharma, a publicly traded biotechnology firm (OTCQB:VODG), develops technology and products derived from adult stem cells and is currently focused on mesenchymal stem cells (MSCs). MSCs have numerous applications in treatment of a variety of medical conditions, including injuries or diseases of the joints, heart, kidney, liver and lung failure, MS, stroke, cancer, hearing loss, and various other regenerative medicine applications. MSCs may be derived from an individual patient, expanded and then transplanted back to that patient to treat injury or disease through regeneration or repair of specific cells. Vitro manufactures and distributes to global markets a series of ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Capricor

Los Angeles-based Capricor is a privately held biotechnology company that aims to create powerful, yet easy-to-administer cardiac stem cell treatments to regenerate damaged heart muscle and improve heart function for patients having suffered a heart attack.

Regulus Therapeutics

Regulus is focused on the discovery and development of microRNA therapeutics. microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome.  A single microRNA can target and regulate up to hundreds of genes, and these genes are involved in biological networks or pathways.  Dysregulated microRNA expression is involved in the initiation of many complex multi-factoral diseases, including cancer, inflammatory disease, fibrosis, and metabolic disease. microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat  human disease. Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS).  Regulus benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. Regulus has access to over 900 patents and patent applications pertaining to oligonucleotide technologies useful for targeting microRNA therapeutics, and over 170 patents and patent applications directed to microRNA specific technologies. Regulus is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and drug development. Regulus’ scientific advisory board consists of world-class scientists and several of the foremost authorities in the field of microRNA research.  

Encore Rehabilitation

Encore Rehabilitation is a Berkley, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aradigm Corporation

Aradigm Corporation is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provident Research

We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.